SUPN News and Press, Supernus Pharmaceuticals Inc. From 11/07/23

2023-11-07 17:35:55 ET More on Supernus Pharmaceuticals Supernus: Product Sales Stretching Higher, But Not Reflected In Economic Leverage Supernus resubmits NDA for Parkinson's disease infusion device EU regulators warn pregnant women not to use topiramate Se...

ROCKVILLE, Md., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Super...

ROCKVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (F...

ROCKVILLE, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial ...

Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree 15.7 million U.S. children, teens and adults estimated to have been diagnosed with ADHD 1,2 ROCKVILLE, Md., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Television personality a...

2023-10-09 17:37:36 ET More on Supernus Pharmaceuticals Supernus: Product Sales Stretching Higher, But Not Reflected In Economic Leverage Supernus Pharmaceuticals, Inc. (SUPN) Q2 2023 Earnings Call Transcript EU regulators warn pregnant women not to use topiramate ...

ROCKVILLE, Md., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will host and webcast a Research &am...

Topline results from Phase IV study demonstrate Qelbree is safe and well-tolerated, and significantly improved efficacy outcomes when added to a stimulant medication in pediatric patients with ADHD Final long-term data show Qelbree consistently improved symptoms and executive function in ...

2023-09-01 22:07:06 ET Summary Supernus Pharmaceuticals specializes in developing and commercializing treatments for CNS disorders, with 8 commercial products in the market. The company's Q2 FY'23 revenues declined by 20% due to a decrease in Trokendi XR product sales. Economi...

2023-09-01 10:47:51 ET The European Medicines Agency’s safety committee has recommended that pregnant women avoid using products containing topiramate due to concerns that it may cause neurodevelopmental disorders in children exposed to the drug while in the womb. Topiramate is a...